Article Text

Download PDFPDF

P176 Percutaneous microwave ablation of painful spinal metastasis: an updated systematic review of analgesia and safety
Free
  1. Jacopo Scaggiante1,
  2. Alessandro Pedicelli2,
  3. Salvatore Marsico3,
  4. Calogero Casà4,
  5. Francesco Miccichè4,
  6. Giuseppe Garignano1,
  7. Andrea Alexandre2,
  8. Iacopo Valente1,
  9. Francesco D’argento5,
  10. Monica Ferrante1,
  11. Evis Sala1,
  12. Ettore Squillaci4
  1. 1Agostino Gemelli University Polyclinic, Rome, Italy
  2. 2Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  3. 3Hospital del Mar, Barcelona, Spain
  4. 4Tiber Island Hospital – Gemelli Island, Roma RM, Italy
  5. 5Agostino Gemelli University Policlinic, Rome, Italy

Abstract

Introduction Microwave ablation (MWA) is a promising minimally invasive technique for treating spinal metastases, creating larger ablation zones, reducing procedural times, and effectively ablating high-impedance tissues.

Aim of Study To evaluate the efficacy and safety of MWA in managing pain associated with spinal metastases.

Methods A systematic search and analysis were conducted following PRISMA guidelines. Studies were included if they met the following criteria:

  • Randomized or non-randomized studies with at least 3 patients (prospective or retrospective)

  • Adult patients with spinal metastases

  • MWA used alone or combined with other treatments

  • Reported pre- and post-MWA pain assessments

  • Published in English

Data on demographics, tumor type, lesion location, pain scores, and complications were extracted.

Results The search yielded 14 studies encompassing over 481 patients(M:F=1:1) with 836 treated lesions. All studies reported achieving partial pain response based on International Consensus Endpoint after Radiation Therapy criteria. Additionally, 85.7% of studies showed highly effective pain management (≥4-point reduction on a pain scale to the last follow-up). Lung(35.4%), breast(25%), and gastrointestinal(12.5%) cancers were the most common primary tumors. The thoracic spine was the most frequent site (47%), followed by lumbar (41.3%) and sacral (11.2%). No major complications were observed.

Conclusion This systematic review suggests that MWA, often used in combination with vertebral augmentation, represents a safe and effective treatment for achieving short- to mid-term (24 hours to 6 months) pain control in patients with spinal metastases.

Disclosure of Interest no.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.